BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group., Tuberculosis Trials Consortium. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr 2015;169:247-55. [PMID: 25580725 DOI: 10.1001/jamapediatrics.2014.3158] [Cited by in Crossref: 108] [Cited by in F6Publishing: 88] [Article Influence: 15.4] [Reference Citation Analysis]
Number Citing Articles
1 Bothamley GH. Fluoroquinolone Preventive Therapy after Exposure to Multidrug-Resistant Tuberculosis? Hopes and Fears. Am J Respir Crit Care Med 2015;192:131-2. [PMID: 26177170 DOI: 10.1164/rccm.201505-0863ED] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Domínguez J, Latorre I, Santin M. Diagnosis and therapeutic approach of latent tuberculosis infection. Enfermedades infecciosas y microbiologia clinica (English ed ) 2018;36:302-11. [DOI: 10.1016/j.eimce.2017.11.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Malik AA, Farooq S, Jaswal M, Khan H, Nasir K, Fareed U, Shahbaz S, Amanullah F, Safdar N, Khan AJ, Keshavjee S, Becerra MC, Hussain H. Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health 2021;5:350-6. [PMID: 33770510 DOI: 10.1016/S2352-4642(21)00052-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Alfarisi O, Alghamdi WA, Al-Shaer MH, Dooley KE, Peloquin CA. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? Expert Rev Clin Pharmacol 2017;10:1027-36. [PMID: 28803492 DOI: 10.1080/17512433.2017.1366311] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
5 Mehaffy C, Kruh-Garcia NA, Graham B, Jarlsberg LG, Willyerd CE, Borisov A, Sterling TR, Nahid P, Dobos KM. Identification of Mycobacterium tuberculosis Peptides in Serum Extracellular Vesicles from Persons with Latent Tuberculosis Infection. J Clin Microbiol 2020;58:e00393-20. [PMID: 32245831 DOI: 10.1128/JCM.00393-20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
6 Venturini E, Tersigni C, Chiappini E, de Martino M, Galli L. Optimizing the management of children with latent tuberculosis infection. Expert Rev Anti Infect Ther 2017;15:341-9. [PMID: 28074660 DOI: 10.1080/14787210.2017.1279541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Egelund EF, Peloquin CA. Rifapentine for the treatment of latent tuberculosis. Expert Rev Clin Pharmacol 2016;9:1253-61. [PMID: 27545595 DOI: 10.1080/17512433.2016.1222270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Gaensbauer J, Broadhurst R. Recent Innovations in Diagnosis and Treatment of Pediatric Tuberculosis. Curr Infect Dis Rep 2019;21:4. [PMID: 30767077 DOI: 10.1007/s11908-019-0662-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
9 Campbell JI, Sandora TJ, Haberer JE. A scoping review of paediatric latent tuberculosis infection care cascades: initial steps are lacking. BMJ Glob Health 2021;6:e004836. [PMID: 34016576 DOI: 10.1136/bmjgh-2020-004836] [Reference Citation Analysis]
10 Rabahi MF, Silva Júnior JLRD, Ferreira ACG, Tannus-Silva DGS, Conde MB. Tuberculosis treatment. J Bras Pneumol 2017;43:472-86. [PMID: 29340497 DOI: 10.1590/S1806-37562016000000388] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 6.7] [Reference Citation Analysis]
11 Hein DW, Millner LM. Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review. Expert Opin Drug Metab Toxicol 2021;17:9-21. [PMID: 33094670 DOI: 10.1080/17425255.2021.1840551] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Seddon JA, Schaaf HS. Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis. Pneumonia (Nathan) 2016;8:20. [PMID: 28702299 DOI: 10.1186/s41479-016-0019-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
13 Alvarez GG, Van Dyk D, Mallick R, Lesperance S, Demaio P, Finn S, Potvin SE, Patterson M, Pease C, Amaratunga K, Hui C, Cameron DW, Mulpuru S, Aaron SD, Momoli F, Zwerling A. The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study. Int J Circumpolar Health 2020;79:1758501. [PMID: 32379538 DOI: 10.1080/22423982.2020.1758501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 Radtke KK, Hibma JE, Hesseling AC, Savic RM. Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children. Eur Respir J 2021;57:2001756. [PMID: 32703775 DOI: 10.1183/13993003.01756-2020] [Reference Citation Analysis]
15 Yang H, Yang Y, Hu ZD, Xia L, Liu XH, Yu X, Ma JY, Li T, Lu SH. High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-A single center study. PLoS One 2021;16:e0253159. [PMID: 34115804 DOI: 10.1371/journal.pone.0253159] [Reference Citation Analysis]
16 Matteelli A, Sulis G, Capone S, D'Ambrosio L, Migliori GB, Getahun H. Tuberculosis elimination and the challenge of latent tuberculosis. Presse Med 2017;46:e13-21. [PMID: 28279508 DOI: 10.1016/j.lpm.2017.01.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
17 Dubois M, Dixit A, Lamb G. Tuberculosis in Pediatric Solid Organ and Hematopoietic Stem Cell Recipients. Glob Pediatr Health 2021;8:2333794X20981548. [PMID: 33506075 DOI: 10.1177/2333794X20981548] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Lamb GS, Starke JR. Tuberculosis in Infants and Children. Microbiol Spectr 2017;5. [PMID: 28387193 DOI: 10.1128/microbiolspec.TNMI7-0037-2016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 3.4] [Reference Citation Analysis]
19 Szkwarko D, Hirsch-Moverman Y, Du Plessis L, Du Preez K, Carr C, Mandalakas AM. Child contact management in high tuberculosis burden countries: A mixed-methods systematic review. PLoS One 2017;12:e0182185. [PMID: 28763500 DOI: 10.1371/journal.pone.0182185] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 8.8] [Reference Citation Analysis]
20 Marais BJ. Preventing tuberculosis in household contacts crucial to protect children and contain epidemic spread. Lancet Glob Health 2018;6:e1260-1. [PMID: 30266569 DOI: 10.1016/S2214-109X(18)30449-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Donald PR, Ronge L, Demers AM, Thee S, Schaaf HS, Hesseling AC. Positive Mycobacterium tuberculosis Gastric Lavage Cultures from Asymptomatic Children With Normal Chest Radiography. J Pediatric Infect Dis Soc 2021;10:502-8. [PMID: 33079203 DOI: 10.1093/jpids/piaa113] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Njie GJ, Morris SB, Woodruff RY, Moro RN, Vernon AA, Borisov AS. Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. Am J Prev Med 2018;55:244-52. [PMID: 29910114 DOI: 10.1016/j.amepre.2018.04.030] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
23 Khatua S, Geltemeyer AM, Gourishankar A. Tuberculosis: Is the landscape changing? Pediatr Res 2017;81:265-70. [PMID: 27723725 DOI: 10.1038/pr.2016.205] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
24 Ortblad KF, Salomon JA, Bärnighausen T, Atun R. Stopping tuberculosis: a biosocial model for sustainable development. Lancet 2015;386:2354-62. [PMID: 26515678 DOI: 10.1016/S0140-6736(15)00324-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
25 Otero L, Battaglioli T, Ríos J, De la Torre Z, Trocones N, Ordoñez C, Seas C, Van der Stuyft P. Contact evaluation and isoniazid preventive therapy among close and household contacts of tuberculosis patients in Lima, Peru: an analysis of routine data. Trop Med Int Health 2020;25:346-56. [PMID: 31758837 DOI: 10.1111/tmi.13350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
26 Yuen CM, Seddon JA, Keshavjee S, Dodd PJ. Risk-benefit analysis of tuberculosis infection testing for household contact management in high-burden countries: a mathematical modelling study. Lancet Glob Health 2020;8:e672-80. [PMID: 32353315 DOI: 10.1016/S2214-109X(20)30075-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Grace SG. Barriers to the implementation of isoniazid preventive therapy for tuberculosis in children in endemic settings: A review. J Paediatr Child Health 2019;55:278-84. [PMID: 30604557 DOI: 10.1111/jpc.14359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
28 Holmberg PJ, Temesgen Z, Banerjee R. Tuberculosis in Children. Pediatr Rev 2019;40:168-78. [PMID: 30936398 DOI: 10.1542/pir.2018-0093] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
29 Moscibrodzki P, Enane LA, Hoddinott G, Brooks MB, Byron V, Furin J, Seddon JA, Meyersohn L, Chiang SS. The Impact of Tuberculosis on the Well-Being of Adolescents and Young Adults. Pathogens 2021;10:1591. [PMID: 34959546 DOI: 10.3390/pathogens10121591] [Reference Citation Analysis]
30 Campbell JR, Trajman A, Cook VJ, Johnston JC, Adjobimey M, Ruslami R, Eisenbeis L, Fregonese F, Valiquette C, Benedetti A, Menzies D. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis 2020;20:318-29. [PMID: 31866327 DOI: 10.1016/S1473-3099(19)30575-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
31 Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR Jr, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020;69:1-11. [PMID: 32053584 DOI: 10.15585/mmwr.rr6901a1] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 27.0] [Reference Citation Analysis]
32 Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, Skidmore B, Alvarez GG. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf 2018;27:557-66. [DOI: 10.1002/pds.4423] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
33 Cruz AT, Starke JR. Safety and Adherence for 12 Weekly Doses of Isoniazid and Rifapentine for Pediatric Tuberculosis Infection. Pediatric Infectious Disease Journal 2016;35:811-3. [DOI: 10.1097/inf.0000000000001164] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
34 Barry PM, Kay AW, Flood JM, Watt J. Getting to Zero: Tuberculosis Elimination in California. Curr Epidemiol Rep 2016;3:136-44. [PMID: 27218013 DOI: 10.1007/s40471-016-0076-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
35 Miranda C, Bark CM. TB, or not TB, the Choice Is Ours. Clin Infect Dis 2020;71:291-2. [PMID: 31584625 DOI: 10.1093/cid/ciz819] [Reference Citation Analysis]
36 Seddon JA, McKenna L, Shah T, Kampmann B. Recent Developments and Future Opportunities in the Treatment of Tuberculosis in Children. Clin Infect Dis 2015;61Suppl 3:S188-99. [PMID: 26409282 DOI: 10.1093/cid/civ582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
37 Marais BJ. Newer Drugs for Tuberculosis Prevention and Treatment in Children. Indian J Pediatr 2019;86:725-31. [PMID: 30707347 DOI: 10.1007/s12098-018-02854-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
38 Turetz ML, Ma KC. Diagnosis and management of latent tuberculosis. Curr Opin Infect Dis 2016;29:205-11. [PMID: 26836374 DOI: 10.1097/QCO.0000000000000253] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
39 Ilievska-Poposka B, Metodieva M, Zakoska M, Vragoterova C, Trajkov D. Latent Tuberculosis Infection - Diagnosis and Treatment. Open Access Maced J Med Sci 2018;6:651-5. [PMID: 29731933 DOI: 10.3889/oamjms.2018.161] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
40 Fernandes GFDS, Salgado HRN, Santos JLD. Isoniazid: A Review of Characteristics, Properties and Analytical Methods. Crit Rev Anal Chem 2017;47:298-308. [PMID: 28080136 DOI: 10.1080/10408347.2017.1281098] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
41 Smith M, Accinelli A, Tejada F, Kharel M. Drugs Used in Tuberculosis and Leprosy. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Elsevier; 2016. pp. 283-93. [DOI: 10.1016/bs.seda.2016.08.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
42 Jo KW, Kim JS, Kwon HS, Park YE, Kim JY, Hong MJ, Shim TS. Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers. Respir Med 2019;158:42-8. [PMID: 31605920 DOI: 10.1016/j.rmed.2019.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
43 Salazar-Austin N, Dowdy DW, Chaisson RE, Golub JE. Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration. Am J Epidemiol 2019;188:2078-85. [PMID: 31364692 DOI: 10.1093/aje/kwz172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Fry SH, Barnabas SL, Cotton MF. Tuberculosis and HIV-An Update on the "Cursed Duet" in Children. Front Pediatr 2019;7:159. [PMID: 32211351 DOI: 10.3389/fped.2019.00159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
45 Alvarez GG. TB in Canada-The battle is not over. Can Commun Dis Rep 2015;41:16-8. [PMID: 29769958 DOI: 10.14745/ccdr.v41is2a03] [Reference Citation Analysis]
46 Amaratunga KR, Alvarez GG. Primary care pearls to help eliminate tuberculosis in Canada. Can Commun Dis Rep 2016;42:63-7. [PMID: 29770006 DOI: 10.14745/ccdr.v42i03a03] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Sanju Sv C, Srinivasapura Venkateshmurthy N, Nair D, Hari Ankolekar V, Mv Kumar A. What Proportion of New Tuberculosis Patients Has a History of Household Tuberculosis Exposure? A Cross-Sectional Study from Udupi District, South India. Trop Med Infect Dis 2019;4:E133. [PMID: 31683771 DOI: 10.3390/tropicalmed4040133] [Reference Citation Analysis]
48 Chiang SS, Starke JR. Mycobacterium tuberculosis. Principles and Practice of Pediatric Infectious Diseases. Elsevier; 2018. pp. 790-806.e5. [DOI: 10.1016/b978-0-323-40181-4.00134-1] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
49 Davies MA, Pinto J, Bras M. Getting to 90-90-90 in paediatric HIV: What is needed? J Int AIDS Soc 2015;18:20770. [PMID: 28326130 DOI: 10.7448/IAS.18.7.20770] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
50 Jain A, Lodha R. Management of Latent Tuberculosis Infection in Children from Developing Countries. Indian J Pediatr 2019;86:740-5. [PMID: 30741387 DOI: 10.1007/s12098-019-02861-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
51 Fox GJ, Dobler CC, Marais BJ, Denholm JT. Preventive therapy for latent tuberculosis infection-the promise and the challenges. Int J Infect Dis 2017;56:68-76. [PMID: 27872018 DOI: 10.1016/j.ijid.2016.11.006] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 12.2] [Reference Citation Analysis]
52 Mathew JL, John TJ, Parakh A. Intermittent Short Course Rifapentine-Isoniazid Combination for Preventing Tuberculosis in Children: Evidence based Medicine Viewpoint. Indian Pediatr 2015;52:421-5. [PMID: 26061929 DOI: 10.1007/s13312-015-0648-4] [Reference Citation Analysis]
53 Thomas TA. Tuberculosis in Children. Thorac Surg Clin 2019;29:109-21. [PMID: 30454917 DOI: 10.1016/j.thorsurg.2018.09.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
54 Seddon JA, Paton J, Nademi Z, Keane D, Williams B, Williams A, Welch SB, Liebeschutz S, Riddell A, Bernatoniene J, Patel S, Martinez-Alier N, McMaster P, Kampmann B. The impact of BCG vaccination on tuberculin skin test responses in children is age dependent: evidence to be considered when screening children for tuberculosis infection. Thorax 2016;71:932-9. [PMID: 27335104 DOI: 10.1136/thoraxjnl-2015-207687] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
55 Schaaf H, Garcia-prats A, Donald P. Antituberculosis drugs in children. Clin Pharmacol Ther 2015;98:252-65. [DOI: 10.1002/cpt.164] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
56 Pease C, Amaratunga KR, Alvarez GG. A shorter treatment regimen for latent tuberculosis infection holds promise for at-risk Canadians. Can Commun Dis Rep 2017;43:67-71. [PMID: 29770067 DOI: 10.14745/ccdr.v43i34a02] [Reference Citation Analysis]
57 Nolt D, Starke JR. Tuberculosis Infection in Children and Adolescents: Testing and Treatment. Pediatrics 2021;148:e2021054663. [PMID: 34851422 DOI: 10.1542/peds.2021-054663] [Reference Citation Analysis]
58 Hatzenbuehler LA, Starke JR, Graviss EA, Smith EO, Cruz AT. School-based Study to Identify and Treat Adolescent Students at Risk for Tuberculosis Infection. Pediatr Infect Dis J 2016;35:733-8. [PMID: 27078123 DOI: 10.1097/INF.0000000000001151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
59 Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Miró JM, Villarino ME, Weiner M, Borisov AS; TB Trials Consortium iAdhere Study Team. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. Ann Intern Med 2017;167:689-97. [PMID: 29114781 DOI: 10.7326/M17-1150] [Cited by in Crossref: 60] [Cited by in F6Publishing: 35] [Article Influence: 12.0] [Reference Citation Analysis]
60 Seddon JA, Graham SM. Childhood TB: can the End TB Strategy deliver? Trans R Soc Trop Med Hyg 2016;110:155-7. [PMID: 26884493 DOI: 10.1093/trstmh/trw007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
61 Seddon JA, Whittaker E, Kampmann B, Lewinsohn DA, Osman M, Hesseling AC, Rustomjee R, Amanullah F. The evolving research agenda for paediatric tuberculosis infection. Lancet Infect Dis 2019;19:e322-9. [PMID: 31221543 DOI: 10.1016/S1473-3099(18)30787-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
62 Gao L, Zhang H, Xin H, Liu J, Pan S, Li X, Guan L, Shen F, Liu Z, Wang D, Guan X, Yan J, Li H, Feng B, Cao X, Chen Y, Cui W, Zhang Z, Ma Y, Chen X, Zhou X, Jin Q; LATENTTB-NSTM study team. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J 2018;52:1801470. [PMID: 30361241 DOI: 10.1183/13993003.01470-2018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
63 Hatzenbuehler LA, Starke JR. Treatment of tuberculosis infection in children. Expert Rev Anti Infect Ther 2018;16:695-708. [PMID: 30132364 DOI: 10.1080/14787210.2018.1513324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
64 Lai EC, Liang HY, Huang YC, Huang WI, Chao PH, Chen WW, Weng MY. Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors. Sci Rep 2021;11:18013. [PMID: 34504225 DOI: 10.1038/s41598-021-97444-8] [Reference Citation Analysis]
65 Peck GM, Staat MA, Huang FS, Khalil N, Boyce C, Kohlrieser CM, Schlaudecker EP. Adverse events associated with weekly short course isoniazid and rifapentine therapy in pediatric patients with latent tuberculosis: A chart and literature review. Pediatr Pulmonol 2021;56:2695-9. [PMID: 33969644 DOI: 10.1002/ppul.25456] [Reference Citation Analysis]
66 Kendall EA, Hussain H, Kunkel A, Kubiak RW, Trajman A, Menzies R, Drain PK. Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis. BMC Med 2021;19:315. [PMID: 34903214 DOI: 10.1186/s12916-021-02189-w] [Reference Citation Analysis]
67 Garessus EDG, Mielke H, Gundert-Remy U. Exposure of Infants to Isoniazid via Breast Milk After Maternal Drug Intake of Recommended Doses Is Clinically Insignificant Irrespective of Metaboliser Status. A Physiologically-Based Pharmacokinetic (PBPK) Modelling Approach to Estimate Drug Exposure of Infants via Breast-Feeding. Front Pharmacol 2019;10:5. [PMID: 30723406 DOI: 10.3389/fphar.2019.00005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
68 Thomas TA. Tuberculosis in Children. Pediatr Clin North Am 2017;64:893-909. [PMID: 28734517 DOI: 10.1016/j.pcl.2017.03.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
69 Cruz AT, Starke JR. Window Period Prophylaxis for Children Exposed to Tuberculosis, Houston, Texas, USA, 2007-2017. Emerg Infect Dis 2019;25:523-8. [PMID: 30789136 DOI: 10.3201/eid2503.181596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Money NM, Schroeder AR, Quinonez RA, Ho T, Marin JR, Morgan DJ, Dhruva SS, Coon ER. 2019 Update on Pediatric Medical Overuse: A Systematic Review. JAMA Pediatr 2020;174:375. [DOI: 10.1001/jamapediatrics.2019.5849] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
71 Domínguez J, Latorre I, Santin M. Diagnóstico y abordaje terapéutico de la infección tuberculosa latente. Enfermedades Infecciosas y Microbiología Clínica 2018;36:302-11. [DOI: 10.1016/j.eimc.2017.11.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
72 Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, Yelk Woodruff R, Allen L, LoBue P, Vernon A. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection. MMWR Morb Mortal Wkly Rep 2018;67:723-6. [PMID: 29953429 DOI: 10.15585/mmwr.mm6725a5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 12.8] [Reference Citation Analysis]
73 Cole B, Nilsen DM, Will L, Etkind SC, Burgos M, Chorba T. Essential Components of a Public Health Tuberculosis Prevention, Control, and Elimination Program: Recommendations of the Advisory Council for the Elimination of Tuberculosis and the National Tuberculosis Controllers Association. MMWR Recomm Rep 2020;69:1-27. [PMID: 32730235 DOI: 10.15585/mmwr.rr6907a1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Daley CL. The Global Fight Against Tuberculosis. Thorac Surg Clin 2019;29:19-25. [PMID: 30454918 DOI: 10.1016/j.thorsurg.2018.09.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
75 Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, Skidmore B, Moher D, Alvarez GG. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis 2017;17:265. [PMID: 28399802 DOI: 10.1186/s12879-017-2377-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
76 Tseng SY, Huang YS, Chang TE, Perng CL, Huang YH. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis. J Chin Med Assoc 2021;84:993-1000. [PMID: 34747900 DOI: 10.1097/JCMA.0000000000000605] [Reference Citation Analysis]
77 Fry S, Barnabas S, Cotton MF. Update on trends in childhood tuberculosis. Curr Opin Pediatr 2018;30:152-60. [PMID: 29194073 DOI: 10.1097/MOP.0000000000000581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR, Crane CM, Burgos M, Lobue P, Winston CA, Belknap R. Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. Am J Transplant 2020;20:1196-206. [DOI: 10.1111/ajt.15841] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
79 Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, Chen MP, Benator DA, Gordin F, Benson CA, Chaisson RE, Villarino ME; Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259) The investigators of the TB Trials Consortium and the AIDS Clinical Trials Group for the PREVENT TB Trial are listed in the Supplement, item 17. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS 2016;30:1607-15. [PMID: 27243774 DOI: 10.1097/QAD.0000000000001098] [Cited by in Crossref: 80] [Cited by in F6Publishing: 35] [Article Influence: 16.0] [Reference Citation Analysis]
80 Dorjee K, Topgyal S, Dorjee C, Tsundue T, Namdol T, Tsewang T, Nangsel T, Lhadon D, Choetso T, Dawa T, Phentok T, DeLuca AN, Tsering L, Phunkyi D, Sadutshang TD, J Bonomo E, Paster Z, Chaisson RE. High Prevalence of Active and Latent Tuberculosis in Children and Adolescents in Tibetan Schools in India: The Zero TB Kids Initiative in Tibetan Refugee Children. Clin Infect Dis 2019;69:760-8. [PMID: 30462191 DOI: 10.1093/cid/ciy987] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
81 Romero-Cordero S, Kirwan R, Noguera-Julian A, Cardellach F, Fortuny C, Morén C. A Mitocentric View of the Main Bacterial and Parasitic Infectious Diseases in the Pediatric Population. Int J Mol Sci 2021;22:3272. [PMID: 33806981 DOI: 10.3390/ijms22063272] [Reference Citation Analysis]
82 Walker RE, Bass S, Srinivas P, Miranda C, Johnson L, Pallotta AM. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection. Ann Pharmacother 2020;54:457-63. [DOI: 10.1177/1060028019888855] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
83 Menzies D, Trajman A. New short regimens for latent tuberculosis treatment: safety first! Eur Respir J 2018;52:1802180. [PMID: 30573695 DOI: 10.1183/13993003.02180-2018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
84 Kitai I, Morris SK, Kordy F, Lam R. Diagnosis and management of pediatric tuberculosis in Canada. CMAJ 2017;189:E11-6. [PMID: 28246254 DOI: 10.1503/cmaj.151212] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
85 Ruan QL, Huang XT, Yang QL, Liu XF, Wu J, Pan KC, Shen YJ, Cai LM, Ling Q, Jiang T, Hong JJ, Wang XD, Ma CL, Peng GQ, Wang XZ, Mao JC, Wu TZ, Lin MY, Shao LY, Zhang WH. Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients: a randomized controlled trial. Clin Microbiol Infect 2021;27:576-82. [PMID: 32553881 DOI: 10.1016/j.cmi.2020.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
86 Lee MR, Huang HL, Lin SW, Cheng MH, Lin YT, Chang SY, Yan BS, Kuo CH, Lu PL, Wang JY, Chong IW. Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI. J Clin Med 2019;8:E812. [PMID: 31174321 DOI: 10.3390/jcm8060812] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
87 Cruz AT, Starke JR. Managing tuberculosis infection in children in the USA: an update. Future Microbiol 2016;11:669-84. [PMID: 27164182 DOI: 10.2217/fmb-2016-0027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
88 Haley CA. Treatment of Latent Tuberculosis Infection. Microbiol Spectr 2017;5. [PMID: 28409555 DOI: 10.1128/microbiolspec.TNMI7-0039-2016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
89 Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, Wang SH, Stewart B, Griffin P, Hunt G, Shah N, Marco A, Patil N, Mukasa L, Moro RN, Jereb J, Mase S, Chorba T, Bamrah-Morris S, Ho CS. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection. Clin Infect Dis 2017;65:1085-93. [PMID: 28575208 DOI: 10.1093/cid/cix505] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
90 Dodd PJ, Yuen CM, Becerra MC, Revill P, Jenkins HE, Seddon JA. Potential effect of household contact management on childhood tuberculosis: a mathematical modelling study. Lancet Glob Health 2018;6:e1329-38. [PMID: 30266570 DOI: 10.1016/S2214-109X(18)30401-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 8.3] [Reference Citation Analysis]
91 Kay AW, Thivalapill N, Skinner D, Dube GS, Dlamini N, Mzileni B, Fuentes P, Ustero P, Adams LV, Mandalakas AM. Predictors of suboptimal adherence to isoniazid preventive therapy among adolescents and children living with HIV. PLoS One 2020;15:e0243713. [PMID: 33332462 DOI: 10.1371/journal.pone.0243713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Graham SM. The management of infection with Mycobacterium tuberculosis in young children post-2015: an opportunity to close the policy-practice gap. Expert Review of Respiratory Medicine 2017;11:41-9. [DOI: 10.1080/17476348.2016.1267572] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
93 McAnaw SE, Hesseling AC, Seddon JA, Dooley KE, Garcia-Prats AJ, Kim S, Jenkins HE, Schaaf HS, Sterling TR, Horsburgh CR. Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities. Int J Infect Dis 2017;56:194-9. [PMID: 27955992 DOI: 10.1016/j.ijid.2016.11.423] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
94 Rabie H, Frigati L, Hesseling AC, Garcia-Prats AJ. Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected children. J Int AIDS Soc 2015;18:20236. [PMID: 26639110 DOI: 10.7448/IAS.18.7.20236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
95 Rangaka MX, Cavalcante SC, Marais BJ, Thim S, Martinson NA, Swaminathan S, Chaisson RE. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet 2015;386:2344-53. [PMID: 26515679 DOI: 10.1016/S0140-6736(15)00323-2] [Cited by in Crossref: 99] [Cited by in F6Publishing: 48] [Article Influence: 14.1] [Reference Citation Analysis]